APRIL
11.4.2024 11:59:30 CEST | Business Wire | Press release
Building on the success of its first transformation plan, APRIL is embarking on a new phase in its development with the ambition of becoming a European leader of global stature in the design, distribution and management of insurance solutions and financial products. The Group is planning an ambitious growth cycle, both organic and external, which will take it to a turnover of more than €1 billion by 2027.
With sales of €630m by 2023, 20% of which will be generated outside France, the Spring 2023 strategic plan has enabled APRIL to return to its basics and achieve sustainable growth. Today, the Group is looking ahead to a new stage in its development and has set itself the target of exceeding €1 billion in turnover by 2027.
« In an extremely competitive international environment, one of the most successful insurance brokers is French! Our nearly 3,000 employees are proud to continue APRIL's history and are in action to expand our global footprint, for the benefit of our tens of thousands of partners and our millions of customers, whom we support and protect on a daily basis, » states Eric Maumy, CEO of APRIL.
Four cardinal points to guide the Group's development:
the spirit of conquest, customer delight, technological performance and talent.
The spirit of conquest to become a global consolidator
With its sustained growth, APRIL Group will further accelerate its development based on three principles:
- Organic growth in its traditional markets: health and personal insurance for individuals, professionals and businesses, health insurance for expatriates and property and casualty insurance (auto, 2-wheeler, construction, real estate and yachting).
- Diversification into new growth drivers, as the Group has already begun to do with savings and asset management, which have become the Group's 4th business line.
- Internationalisation in all its markets, starting with international health, with strong ambitions in Europe, the Middle East and Asia.
In terms of diversification and internationalisation, APRIL Group intends to step up its external growth momentum, as demonstrated by the two deals completed since the beginning of 2024 with leading French savings company DLPK and UK two-wheeler specialist Lexham Insurance.
This consolidation drive will naturally go hand in hand with APRIL’s ongoing commitment to defending the interests of customers, particularly in terms of access to quality healthcare for as many people as possible.
Enchanting partners and customers to reinvent the insurance experience
Having improved its Net Promoter Score by more than 20 points in 4 years, the Group wants to accelerate its efforts to improve the experience of its partners and customers, by focusing on 3 key areas:
- Enhancing its service approach (easier access to healthcare networks and to teleconsultation facilities, etc.);
- Improving its digital systems - from the underwriting process to self-care areas and conversational tools;
- Strengthening and continually training the teams in contact with customers and partners, to offer them the very best in technology and human relations.
A technological transformation that incorporates Data & AI
APRIL Group plans to invests €70 million in its digital and technological transformation by 2027 with a twofold aim :
- Capitalising on data and artificial intelligence, via iterative projects that will be carried out within the group in France and internationally across all business lines to identify the potential for creating value for employees, customers and partners;
- Continuing to strengthen cyber security in an environment of heightened threat to all economic players.
Providing employees with a unique experience to attract and retain talent
With an average of 400 new hires per year since 2020, APRIL Group has strengthened its team, in particular by recruiting talent in high-tension professions, notably digital technology within its APRIL X hub and customer relations.
With its ambitions raised to 2027, the Group plans to offer a structured and enriched employee experience based on 3 levers:
- Developing talent through the knowledge factory, which will include strengthening the APRIL University and launching an Apprentice Training Centre;
- Focusing on our employees, with several agreements on intergenerational dynamics and inclusion & diversity, as well as the relocation of the Group's head office to more modern, collaborative offices in Lyon (France);
- Greater sharing of value, with the opening of the capital to all the Group's employees worldwide from April 2024.
True to its roots in the social economy, the Group plans to fuel its sustainable growth with a positive and real impact in terms of CSR, in particular through its APRIL Foundation, which focuses on the contribution of behavioural sciences to health prevention and promotion.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411952024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
